Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018
   Pooled it
2. Pathophysiology of eosinophilic esophagitis: recent advances and their clinical implications.Expert review of clinical immunology · 2019
   Review
3. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.Allergy · 2018
   Review
4. Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis.Clinical reviews in allergy & immunology · 2018
   Review
5. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.American journal of respiratory and critical care medicine · 2017
   Article
6. Eosinophilic Esophagitis and Gastroenteritis.Current allergy and asthma reports · 2015
   Review
7. Non- and semi-invasive methods of monitoring eosinophilic esophagitis.Digestive diseases (Basel, Switzerland) · 2014
   Review
8. Eosinophilic gastrointestinal diseases--clinically diverse and histopathologically confounding.Seminars in immunopathology · 2012
   Article
9. Recent advances in the treatment of eosinophilic esophagitis.Expert review of clinical immunology · 2010
   Review

Corrections and comments

• Comment on
  Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.2008

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as